Dogs and cats.

Symptomatic treatment of seborrhoeic dermatitis.

Do not use in cases of hypersensitivity to corticosteroids, salicylic acid or to any of the excipients.

Do not use on cutaneous ulcers.

Do not use in dogs with demodicosis.

Do not administer to animals weighing less than 3.5 kg body weight.

At the beginning of treatment, existing scale and or exfoliative debris should be removed. Hair surrounding or covering the lesions may need to be clipped to enable the veterinary medicinal product to reach the affected skin.

Seborrhoeic dermatitis may be a primary disorder, but can also occur as a result of underlying disorders or disease processes (e.g. allergic disorders, endocrine disorders, neoplasia). Furthermore, infections (bacterial, parasitic or fungal) commonly occur concurrently with seborrhoeic dermatitis. Therefore it is essential to identify any underlying disease process and initiate specific treatment if considered necessary.

As the minimum body weight for the treatment is 3,5 kg, this product will not be suitable for use in certain patients, such as smaller dogs and cats or those with

extensive lesions. Please check maximum recommended dose in Amounts to be administered and administration route.

Systemic corticosteroid effects are possible, especially when the product is used under an occlusive dressing, on extensive skin lesions, with increased blood flow, or if the product is ingested by licking. Oral ingestion (including licking) of the product by treated animals or animals having contact with treated animals should be avoided. Additional corticosteroid treatment should be used only according to the benefit/risk assessment of the responsible veterinarian. Use with precaution in animals with suspected or confirmed endocrine disorders (i.e. diabetes mellitus; hypo- or hyper-thyroidism, hyperadrenocorticism etc.). Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) should be based on a benefit/risk assessment by the attending veterinarian and subject to regular clinical re-evaluations.

Do not apply in the eyes or on the mucosa. Do not apply the veterinary medicinal product on damaged skin.

This product contains triamcinolone acetonide, salicylic acid and ethanol and may be harmful to children after accidental ingestion. Do not leave the product unattended. In case of accidental ingestion seek medical advice immediately and show the package leaflet or label to the physician.

This product may be harmful to the unborn child. As the product can be absorbed through the skin, pregnant women and women of childbearing potential should not handle this product or restrain the animal during treatment and should avoid contact with the treated animal until at least 4 hours after the application.

This product may be irritating to skin or induce hypersensitivity reactions. People with known hypersensitivity to corticosteroids or salicylic acid should avoid contact with the product.

Avoid skin contact with the product. Wear single-use impermeable gloves when handling the product including rubbing in the affected skin of the animal or restraining the animal during treatment. If contact occurs, wash hands or exposed skin and seek medical advice in case of hypersensitivity reactions or if irritation persists.

This product may be irritating to the eyes. Avoid contact with the eyes including hand-to-eye contact. If contact occurs, rinse with clean water. If eye irritation persists, seek medical advice and show the package leaflet or label to the physician.

This product may be harmful after inhalation, especially for people with asthma. Spray in well-ventilated area. Avoid breathing in the spray-mist.

Treated animals should not be handled and children should not be allowed to play with treated animals until the application site is dry. It is recommended that recently treated animals should not be allowed to sleep with owners, especially children.

Prolonged and extensive use of topical corticosteroid preparations is known to trigger local and systemic effects, including suppression of adrenal function, thinning of the epidermis and delayed healing.

The veterinary medicinal product should not be used during pregnancy and lactation because of possible absorption of triamcinolone acetonide, especially if larger areas of the skin need to be treated.

No data available. Use of additional corticosteroid treatment only according to the benefit/risk assessment of the responsible veterinarian.

Cutaneous use.

Treatment dose is 1 spray pump activation per 1.75 kg body weight; to be administered twice a day.

As the product should be applied twice daily, animals should weigh at least 3.5 kg to allow for 2 spray pump activations per day (1 spray pump activation twice daily).

Make sure the opening of the spray pump points to the area to be treated. Brush the pet’s hair against the natural fur line, then spray the product by holding the pump approximately 10 cm from the area to be treated. Care should be taken to avoid spraying near the face of the animal.

If necessary rub the area gently to ensure the veterinary medicinal product reaches all the affected skin. Let dry. In severe cases in dogs, the effect can be increased by applying a second and third layer immediately after the drying of the first layer, provided that the total number of applied spray activations does not exceed the maximum number (1 spray pump activation per 1.75 kg; to be administered twice a day). One spray pump activation delivers approximately 0.2 ml of product over a circular area of approximately 10 cm diameter.

Treatment should be continued without interruption until a few days after complete disappearance of the clinical symptoms but no longer than 14 days.

Prolonged use of high doses of triamcinolone can induce adrenal insufficiency.